跳至主要内容
临床试验/ISRCTN18326338
ISRCTN18326338终止未知

Role of electrical stimulation in enhancement of cutaneous wound healing and engraftment: Accelerated healing by secondary intention and dermal substitute-assisted tissue regeneration in cutaneous wounds

Accel-Heal® Technologies Ltd0 个研究点目标入组 20 人开始时间: 2021年8月20日最近更新:
适应症

试验速览

阶段
未知
状态
终止
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Male and female subjects will be included to allow for gender demographic analysis.
  • 2. Subjects of either gender who are 18 years and older.
  • 3. Subjects who in the opinion of the investigator, are able to fully understand the study requirements and attend all follow-up visits.
  • 4. Subjects must provide written informed consent to participate in the study.
  • 5. Subjects weighing between 40 and 150kg, with a body mass index of 20-35kg/m2 (as described in the Quetelet’sindexQuetelet’s index – weight (kg)/height²(m)).

排除标准

  • 1. Subjects who do not give consent or withdraw their consent to take part in the study.
  • 2. Subjects of either gender who are less than 18 years old.
  • 3. Subjects who have a history of keloid scarring.
  • 4. Subjects who are pregnant or planning to conceive in the next 3 months.
  • 5. Subjects who have a chronic or active skin disorder which may be considered to adversely affect the healing rate of the acute wound by the investigator.
  • 6. Subjects with any likely wound healing impairment due to a clinically significant medical condition such as renal, hepatic, haematological, neurological or immune disease, including:
  • 7. Rheumatoid arthritis
  • 8. Chronic renal impairment
  • 9. Diabetes Mellitus
  • 10. Significant hepatic impairment
  • 11. Inadequately or uncontrolled congestive heart failure
  • 12. Malignancy – diagnosed or treated within the past 5 years.
  • 13. Immunosuppressive, radiation or chemotherapy within the last three months.
  • 14. Subjects who take medication known to alter/influence the healing of skin (e.g. steroids)
  • 15. Subjects who are receiving formal oral anticoagulant therapy (warfarin).
  • 16. Subjects who have received any investigational drugs, or have taken any in the previous month prior to day 0.
  • 17. Subjects who have evidence of drug abuse.
  • 18. Subjects who have had or are known to have hepatitis B or hepatitis C infection including carriers of hepatitis B surface antigen, hepatitis B core antibodies or hepatitis C antibodies. Previous vaccination against hepatitis B or C is not excluded.
  • 19. Subjects who have previously had a positive result to the HIV antibody test, or admit to belong to a high risk group.
  • 20. Any subject, who in the opinion of the investigator is unable to fully understand the requirements of the trial, consent or is unable to return for follow-up visits and complete the trial.
  • 21. Subjects who become systemically unwell during the research process due to external study causes.
  • 22. Subjects who have been involved in other studies in the past month prior to day 0 must discuss the exact details of the previous studies prior to a decision being made on eligibility for inclusion in this trial.
  • 23. Subjects with known severe allergies to antibiotics as the skin substitutes may contain antibiotic residuals from processing.
  • 24. Patients who are allergic to other amide local anaesthetics.
  • 25. Previous MRSA colonisation or infection
  • 26. Any bleeding disorders
  • 27. Subjects with any heart conditions
  • 28. Subjects who have a pacemaker inserted
  • 29. Subjects who have epilepsy
  • 30. Subjects who currently have cancer

研究者

发起方
Accel-Heal® Technologies Ltd

相似试验

The role of electrical stimulation and skin... | 临床试验